The Prevalence of Celiac Disease in a Fracture Liaison Service Population
- PMID: 32725291
- PMCID: PMC7497300
- DOI: 10.1007/s00223-020-00725-z
The Prevalence of Celiac Disease in a Fracture Liaison Service Population
Abstract
Celiac disease (CD) is a known risk factor for osteoporosis and fractures. The prevalence of CD in patients with a recent fracture is unknown. We therefore systematically screened patients at a fracture liaison service (FLS) to study the prevalence of CD. Patients with a recent fracture aged ≥ 50 years were invited to VieCuri Medical Center's FLS. In FLS attendees, bone mineral density (BMD) and laboratory evaluation for metabolic bone disorders and serological screening for CD was systematically evaluated. If serologic testing for CD was positive, duodenal biopsies were performed to confirm the diagnosis CD. Data were collected in 1042 consecutive FLS attendees. Median age was 66 years (Interquartile range (IQR) 15), 27.6% had a major and 6.9% a hip fracture, 26.4% had osteoporosis and 50.8% osteopenia. Prevalent vertebral fractures were found in 29.1%. CD was already diagnosed in two patients (0.19%), one still had a positive serology. Three other patients (0.29%) had a positive serology for CD (one with gastro-intestinal complaints). In two of them, CD was confirmed by duodenal histology (0.19%) and one refused further evaluation. The prevalence of biopsy-proven CD was therefore 0.38% (4/1042) of which 0.19% (2/1042) was newly diagnosed. The prevalence of CD in patients with a recent fracture at the FLS was 0.38% and within the range of reported prevalences in the Western-European population (0.33-1.5%). Newly diagnosed CD was only found in 0.19%. Therefore, standard screening for CD in FLS patients is not recommended.
Keywords: Celiac disease; Fracture liaison service; Fractures; Osteoporosis.
Conflict of interest statement
Dr. Janzing, Dr. Kaarsemaker, Dr. Trienekens, Dr. Vranken, Dr. van der Velde, Dr. Wyers, Dr. Wolters, and Dr. Wouda have nothing to disclose. Dr. de Bruin reports personal fees from Pfizer, personal fees from Novartis, personal fees from Sanofi, outside the submitted work; Dr. van den Bergh reports grants from Amgen, grants from Eli Lilly, grants from UCB, outside the submitted work; Dr. Geusens reports grants and personal fees from Amgen, grants from Pfizer, grants from MSD, grants from UCB, grants from Abbott, grants and personal fees from Lilly, grants from BMS, grants from Novartis, grants from Roche, grants from Will Pharma, outside the submitted work.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
